Mónica Santos, João Sequeira, Pedro Abreu, Rui Guerreiro, Mariana Santos, João Ferreira, Marisa Brum, Filipa Ladeira, Lia Leitão, Rafael Dias, Maria José Sá, Vasco Salgado, Carlos Capela, João de Sá
OBJECTIVES: Cladribine is a selective and oral immunological reconstitution treatment, approved in Europe for very active multiple sclerosis (MS) with relapses. Aims were to assess the safety and effectiveness of cladribine in real-world setting, during treatment follow-up. METHODS: This was a multicentric, longitudinal, observational study with retrospective and prospective data collection of clinical, laboratory, and imaging data. This interim analysis reports data from July 1, 2018 (study onset), to March 31, 2021...
May 2023: Clinical Neuropharmacology